Back to top
more

Zimmer Biomet (ZBH)

(Real Time Quote from BATS)

$121.38 USD

121.38
58,478

+0.53 (0.44%)

Updated May 9, 2024 10:37 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) S.E.T. arm is expected to deliver strong results on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.

    Zimmer (ZBH) Down 5.6% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now

    by Zacks Equity Research

    Investors are optimistic about Zimmer Biomet's (ZBH) better-than-expected revenues and robust performance across several geographies.

    Zimmer Biomet's (ZBH) Procedure Volume Grows, Costs Rise

    by Zacks Equity Research

    Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.

    Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up

    by Zacks Equity Research

    Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.

    Zimmer Biomet (ZBH) Q1 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?

    by Zacks Equity Research

    Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

    by Zacks Equity Research

    DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

    McKesson (MCK) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

    Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Should You Buy?

    by Zacks Equity Research

    Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

    by Zacks Equity Research

    Zimmer Biomet (ZBH) might have struggled to maintain the recovery trend in the first half of Q1 with severe-than-expected staffing shortages and supply issues leading to procedural deferrals.

    PerkinElmer (PKI) to Post Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    PerkinElmer's (PKI) first-quarter results are likely to reflect strong performance at the Diagnostics segment.

    AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

    by Zacks Equity Research

    AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

    The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical

    by Zacks Equity Research

    Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.

    What's in Store for West Pharmaceutical's (WST) Q1 Earnings?

    by Zacks Equity Research

    West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.

    DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.

    Urmimala Biswas headshot

    3 Medical Product Stocks Poised to Beat This Earnings Season

    by Urmimala Biswas

    Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

    Stryker (SYK) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances.

    Baxter (BAX) to Report Q1 Earnings: What's in the Offing?

    by Zacks Equity Research

    Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.

    Here's Why You Should Retain Zimmer Biomet (ZBH) Stock For Now

    by Zacks Equity Research

    Investors are optimistic about Zimmer Biomet (ZBH) given robust demand for its ROSA robotics line and continued investment in profitable business areas.

    What's in Store for Intuitive Surgical's (ISRG) Q1 Earnings?

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) first-quarter results are likely to reflect solid performance in the Instruments & Accessories segment.

    Company News for Apr 6, 2022

    by Zacks Equity Research

    Companies In The News Are: ZBH, CCL, UNH, CHNG, BA.

    Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage

    by Zacks Equity Research

    Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.

    Zimmer Biomet (ZBH) New WalkAI Model to Bolster Robotics Arm

    by Zacks Equity Research

    WalkAI adds powerful predictive analytic capabilities to ZBEdge, Zimmer Biomet's (ZBH) suite of integrated digital and robotic technologies.

    Zimmer (ZBH) Down 3.5% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.